FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Ban on Phenylephrine in Nasal Decongestants

[ Price : $8.95]

Federal Register notice: FDA issues a proposed administrative order to remove orally administered phenylephrine in OTC nasal decon...

Poor Training Found in Lab Inspections

[ Price : $8.95]

FDA cites a lack of adequate training in FY 2023 Good Laboratory Practice inspection form FDA-483s.

FDA Approves J&J Varipulse Platform

[ Price : $8.95]

FDA approves the J&J Varipulse pulsed field ablation platform to treat atrial fibrillation.

Sarepta Scraps Next-Gen Duchenne Drug

[ Price : $8.95]

Based on safety concerns, Sarepta says it is discontinuing the development of SRP-5051 (vesleteplirsen) for treating patients with...

FDA OKs LumiThera Dry AMD Treatment

[ Price : $8.95]

FDA grants de novo authorization to LumiTheras Valeda light delivery treatment for dry age-related macular degeneration.

Caris Companion Diagnostic for Cancer Approved

[ Price : $8.95]

FDA approves Caris Life Sciences MI Cancer Seek and its use as a companion diagnostic to identify cancer patients for treatment wi...

ACLA Views on PCCP Draft Guidance

[ Price : $8.95]

The American Clinical Laboratory Association submits comments to an FDA draft guidance on medical device predetermined change cont...

RFK Jr. Says Some FDA Departments Have to Go

[ Price : $8.95]

In an interview the day after the election, president-elect Donald Trumps top health advisor Robert F. Kennedy Jr. says there are ...

Breakthrough Designation for SeaStar Dialysis Device

[ Price : $8.95]

FDA grants a fourth breakthrough device designation for SeaStar Medicals Selective Cytopheretic Device.

9 Observations in Staska Pharmaceuticals FDA-483

[ Price : $8.95]

FDA releases the form FDA-483 with nine observations from an inspection at the Staska Pharmaceuticals outsourcing facility in Benn...